drugset / Trial / NCT02656160

Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults

NCT02656160

Phase 2 Completed 13 enrolled Brigham and Women's Hospital
RandomizedCrossoverSingle-blindTreatment

Summary

In this protocol the investigators will test the effect of dalfampridine (a potassium channel blocker) on genioglossus muscle activity (EMG GG) during wakefulness and sleep in healthy control subjects.

Timeline

Start
2016-01
Primary completion
2016-05
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dalfampridine Small molecule 10 mg